Quality & safety
Re2O quality and safety: know the origin, understand the risks
Clear information about where Re2O comes from and what is known about its risks.
Product origin
Re2O is developed by L&C BIO and made from processed human dermal tissue. Acellular processing is intended to remove cellular material while retaining a matrix. Tissue origin and processing should be explained openly as part of an informed discussion.
Tissue-bank accreditation, accurately described
The AATB (American Association of Tissue Banks) directory lists L&C Bio Co., Ltd. under accreditation number 00363, with an expiry date of 8 August 2027. The listed scope covers distribution, donor eligibility determination, processing and storage for skin and musculoskeletal tissue. This is accreditation of specified tissue-bank activities; it is not product approval or proof of zero risk.
View the AATB directory entrySafety is part of the conversation
Redness and swelling were reported in the small published clinical study. The absence of serious events in that study does not mean all serious risks have been excluded. A later publication describes a vascular complication after Re2O injection. Re2O should not be described as readily reversible with hyaluronidase. Ask your aesthetic doctor about the risks of the proposed procedure, alternatives and the plan for follow-up or urgent care. Read the safety evidence.
Product questions or concerns
For a packaging, sourcing or product-quality question, contact our team. If you have symptoms after a procedure, contact your treating clinic; seek urgent medical care for concerning symptoms. This website’s general contact form is not an emergency service.